Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nexavar as Adjuvant Treatment in Resected NSCLC (SIRN)
NCT00532025Phase 2Terminated
- Sponsor
- Johannes Gutenberg University Mainz
- Start
- Sep 2007
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sorafenib in non-small cell lung carcinoma (NSCLC), sponsored by Johannes Gutenberg University Mainz. Started Sep 2007; status: terminated.
02
Drugs
sorafenib
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT00532025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00532025.